GM-CSF pathway correction in pulmonary alveolar proteinosis.
about
Clinical significance of serum lipids in idiopathic pulmonary alveolar proteinosis.Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.Pulmonary alveolar proteinosis: diagnostic and therapeutic challenges.Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
P2860
GM-CSF pathway correction in pulmonary alveolar proteinosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
GM-CSF pathway correction in pulmonary alveolar proteinosis.
@en
GM-CSF pathway correction in pulmonary alveolar proteinosis.
@nl
type
label
GM-CSF pathway correction in pulmonary alveolar proteinosis.
@en
GM-CSF pathway correction in pulmonary alveolar proteinosis.
@nl
prefLabel
GM-CSF pathway correction in pulmonary alveolar proteinosis.
@en
GM-CSF pathway correction in pulmonary alveolar proteinosis.
@nl
P2860
P1476
GM-CSF pathway correction in pulmonary alveolar proteinosis.
@en
P2093
Sabina A Antoniu
P2860
P304
P356
10.1517/14712598.2010.510507
P407
P577
2010-09-01T00:00:00Z